Jonathan E. Rosenberg
Led the early enfortumab vedotin trials and the atezolizumab study that first brought immunotherapy to bladder cancer.
Overview
Jonathan Rosenberg led IMvigor210, the first pivotal study of a PD-L1 inhibitor in urothelial cancer, and EV-201, the trial that won enfortumab vedotin accelerated approval, and was a lead investigator of EV-103 and EV-302. He has also led erdafitinib and other FGFR3-directed studies. He chairs GU oncology at MSKCC and the Alliance GU committee.
Pages like this
not linked directly; found by shared links- PersonArjun V. Balar
Shares Atezolizumab, PD-L1, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tags urothelial, immunotherapy.
- PersonThomas Powles
Shares EV-302 / KEYNOTE-A39, Nectin-4, EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer, Enfortumab vedotin and the tags urothelial, adc.
- PersonJoaquim Bellmunt
Shares Bladder & urothelial cancer, Immune checkpoint inhibitors and the tags urothelial, immunotherapy.
- PersonDean F. Bajorin
Shares Memorial Sloan Kettering Cancer Center, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tags urothelial, immunotherapy.
- CompanyEmergence Therapeutics
Shares Nectin-4, Bladder & urothelial cancer, Antibody-drug conjugate (ADC).
- PersonShilpa Gupta
Shares EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer, Enfortumab vedotin, Bladder & urothelial cancer.
- PairingEnfortumab vedotin + pembrolizumab across the bladder cancer continuum
Shares EV-302 / KEYNOTE-A39, Enfortumab vedotin, Bladder & urothelial cancer.
- PersonPeter Schmid
Shares Atezolizumab, PD-L1, Immune checkpoint inhibitors and the tag immunotherapy.